牛牛AI助理已提取核心訊息
On December 31, 2023, Tharimmune, Inc. filed an amendment with the Securities and Exchange Commission (SEC) indicating that Tang Capital Partners, LP, along with its general partner Tang Capital Management, LLC, and their manager Kevin Tang, collectively reported ownership of zero shares of Tharimmune's common stock. The Schedule 13G/A amendment, which updates the group's beneficial ownership information, shows that they do not hold any voting or dispositive power over the company's shares. The filing, dated February 14, 2024, confirms that the parties have ceased to be the beneficial owners of more than five percent of Tharimmune's class of securities and that their holdings do not serve the purpose of changing or influencing the control of the issuer.
On December 31, 2023, Tharimmune, Inc. filed an amendment with the Securities and Exchange Commission (SEC) indicating that Tang Capital Partners, LP, along with its general partner Tang Capital Management, LLC, and their manager Kevin Tang, collectively reported ownership of zero shares of Tharimmune's common stock. The Schedule 13G/A amendment, which updates the group's beneficial ownership information, shows that they do not hold any voting or dispositive power over the company's shares. The filing, dated February 14, 2024, confirms that the parties have ceased to be the beneficial owners of more than five percent of Tharimmune's class of securities and that their holdings do not serve the purpose of changing or influencing the control of the issuer.
2023年12月31日，Tharimmune, Inc.向美國證券交易委員會（SEC）提交了一項修正案，表明唐資本合夥人及其普通合夥人唐資本管理有限責任公司及其經理唐凱文共同報告了Tharimmune普通股零股的所有權。附表13G/A修正案更新了集團的受益所有權信息，表明他們對公司的股票沒有任何投票權或處置權。這份日期爲2024年2月14日的文件證實，雙方已不再是Tharimmune類別證券中超過5％的受益所有人，其持有的並不用於改變或影響發行人的控制權。
2023年12月31日，Tharimmune, Inc.向美國證券交易委員會（SEC）提交了一項修正案，表明唐資本合夥人及其普通合夥人唐資本管理有限責任公司及其經理唐凱文共同報告了Tharimmune普通股零股的所有權。附表13G/A修正案更新了集團的受益所有權信息，表明他們對公司的股票沒有任何投票權或處置權。這份日期爲2024年2月14日的文件證實，雙方已不再是Tharimmune類別證券中超過5％的受益所有人，其持有的並不用於改變或影響發行人的控制權。
有用
沒用